Telavancin: in vitro activity against staphylococci in a biofilm model.
OBJECTIVE
To assess the in vitro activity of the novel lipoglycopeptide telavancin against staphylococcal biofilms using an in vitro pharmacokinetic model.


METHODS
Using the Sorbarod model, biofilms were established. The strains tested included methicillin-susceptible and -resistant strains of Staphylococcus aureus and coagulase-negative staphylococci, as well as glycopeptide-intermediate S. aureus (GISA). The biofilms were exposed to exponentially decreasing concentrations of telavancin and four comparator antibiotics, vancomycin, teicoplanin, linezolid and moxifloxacin and the bactericidal activity of the antibiotics was assessed. The concentrations of the antibiotics used in these experiments corresponded to peak serum levels achievable in humans and the rates at which drug concentrations were decreased corresponded to their elimination half-lives.


RESULTS
All of the drugs tested produced a reduction in the number of bacteria eluted from the biofilms. Telavancin was more effective than the commercially available glycopeptides, vancomycin and teicoplanin, and of the three, was the most active agent against both the non-GISA and GISA strains. Of all the antibiotics tested, moxifloxacin produced the greatest reduction in biofilm cells, but only against the non-GISA strains.


CONCLUSIONS
Telavancin exhibited substantial antimicrobial activity against staphylococcal biofilms, including GISA strains. This study supports the case for the evaluation of telavancin in the treatment of staphylococcal biofilm-associated infections.
Division of Microbiology and Infectious Diseases, Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Nottingham NG5 1PB, UK.
Sarah
S
Gander
Andrew
A
Kinnaird
Roger
R
Finch
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D003030:Coagulase / Q000378:metabolism; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003030:Coagulase; D000077427:Lipoglycopeptides; C487637:telavancin